Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | FASN | P49327 | 1/20 | 0.31 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propionic Acid SCHEMBL4155568 | 0.87 | PIM1 (0.41) | METPIM1PIM2PIKFYVEALDH1A1 | |
| SCHEMBL3247524 | 0.80 | KDM4E (0.35) | METPIM1PIM2FASNPIKFYVE | |
| SCHEMBL4159515 | 0.79 | FFAR1 (0.33) | METKDM4EALDH1A1HPGDLMNA | |
| Propionic Acid SCHEMBL4160296 | 0.79 | GRM5 (0.44) | PIM1FASNMAPT | |
| SCHEMBL3242027 | 0.77 | GABRA1 (0.36) | KDM4EALDH1A1HPGDGLALMNA | |
| Propionic Acid SCHEMBL4160262 | 0.77 | GABRA1 (0.48) | PIM1FASNKDM4EALDH1A1HPGD | |
| Propionic Acid SCHEMBL4165408 | 0.76 | GABRA1 (0.39) | PIM1PIM2FASNKDM4EALDH1A1 | |
| Propionic Acid SCHEMBL4162291 | 0.76 | PDE2A (0.39) | PIKFYVE | |
| Propionic Acid SCHEMBL4155220 | 0.76 | FASN (0.41) | PIM1PIM2FASNBRD4 | |
| Propionic Acid SCHEMBL4159601 | 0.74 | MMP13 (0.42) | BRD4KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | claimed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | MET 1215/4885PIM1 279/4885PIM2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.